Heska (NASDAQ:HSKA)‘s stock had its “buy” rating reiterated by stock analysts at Aegis in a note issued to investors on Tuesday.

Several other research firms also recently issued reports on HSKA. B. Riley reissued a “hold” rating and issued a $96.50 target price on shares of Heska in a research report on Friday, October 27th. Canaccord Genuity initiated coverage on shares of Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price target on the stock. Zacks Investment Research lowered shares of Heska from a “buy” rating to a “hold” rating in a research note on Wednesday, October 4th. Raymond James Financial reissued a “buy” rating on shares of Heska in a research note on Monday, December 4th. Finally, BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $113.30.

Heska (NASDAQ HSKA) traded up $1.51 during trading on Tuesday, reaching $81.72. The company’s stock had a trading volume of 52,300 shares, compared to its average volume of 84,436. The stock has a market capitalization of $590.51, a price-to-earnings ratio of 41.99, a P/E/G ratio of 2.14 and a beta of 0.75. Heska has a one year low of $70.49 and a one year high of $115.00.

Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. The business had revenue of $31.40 million for the quarter, compared to the consensus estimate of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. The business’s quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.45 earnings per share. equities research analysts predict that Heska will post 2.03 EPS for the current year.

In other news, insider Michael J. Mcginley sold 7,826 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 14.70% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of HSKA. Atlantic Trust Group LLC acquired a new stake in Heska in the 3rd quarter valued at approximately $16,059,000. Neuberger Berman Group LLC increased its holdings in Heska by 34.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock valued at $53,160,000 after purchasing an additional 153,895 shares during the last quarter. Vanguard Group Inc. increased its holdings in Heska by 31.7% in the 2nd quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after purchasing an additional 111,232 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Heska by 115.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock valued at $12,266,000 after buying an additional 64,418 shares during the period. Finally, Geneva Advisors LLC boosted its position in Heska by 565.4% in the 2nd quarter. Geneva Advisors LLC now owns 75,499 shares of the medical research company’s stock valued at $7,706,000 after buying an additional 64,153 shares during the period. Hedge funds and other institutional investors own 80.89% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Heska (HSKA) Stock Rating Reaffirmed by Aegis” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/heska-hska-stock-rating-reaffirmed-by-aegis/1776483.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.